S&S On Biotech

When I was a global product manager in big pharma, my US counterpart mentioned to me one day that “we do generics properly in the US, not like you do in Europe.” He meant that when a small molecule went generic in the US, and the 180-day first-to-file exclusivity expired, the former branded price was massacred. It was true, in the first year SmithKline’s Tagamet went generic, they lost 80% of sale...

Has gene therapy delivered on its promise? Or is that promise still to be realised? What are the main problems that limit the safety and efficacy of those gene therapies that have gained approval or are about to do so? And how can the experience the field has gained so far be harnessed to the development of better approaches? Send a text Suggestion box (Suggestions on future episodes, points for c...

Although the Covid-19 pandemic may not be over, it appears to have entered its concluding phase.  Sales of Covid-19 vaccines, as well as therapies, are falling sharply, as are the share prices of their producers. But what are we left with? And what other opportunities are open to the mRNA vaccine technology that performed so powerfully during the pandemic? And how can it be improved?  Send a text...

With nearly three million infections involving antimicrobial resistant bacteria in the US each year and more than 35,000 deaths, you would have thought that the development of new agents to treat antimicrobial resistant infections would be a priority for both governments and biotech companies. But for a number of reasons, it isn’t.  Send a text Suggestion box (Suggestions on future episodes, point...

Skinny jabs. Are they hype, or hope? Send a text Suggestion box (Suggestions on future episodes, points for clarification, comments, etc.) Subscribe (Get notified when new episodes are available. NO marketing!) Disclaimer Ready to create your own impactful podcast series? Contact us at elearningbytes.co.uk to get started!

In the seasonal sequence of biotech fundraising, we are about to enter the ‘back to school’ season where biotech companies that are in need of funding, start their roadshows with institutional investors to gain those funds. Send a text Suggestion box (Suggestions on future episodes, points for clarification, comments, etc.) Subscribe (Get notified when new episodes are available. NO marketing!) Di...